Reza Khademi

Dr. Reza Khademi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
RKReza Khademi
Reza Khademi
AMAli Mirzaei
Ali Mirzaei
AMAmirhossein Mirzaei
Amirhossein Mirzaei
FEFarid Reza Edjlali
Farid Reza Edjlali
Vahid Reza AskariVahid Reza Askari
Vahid Reza Askari
Vafa Baradaran RahimiVafa Baradaran Rahimi
Vafa Baradaran Rahimi

6 May 2025 in Journal of Turkish Society of Obstetric and Gynecology
Verified
Journal Article
Open access
PDF file
SMSeyedeh Tarlan Mirzohreh
Seyedeh Tarlan Mirzohreh
AAArina Ansari
Arina Ansari
HPHana Piroti
Hana Piroti
RKReza Khademi
Reza Khademi
YJYalda Jahanbani
Yalda Jahanbani
PAParvin Bastani Alamdari
Parvin Bastani Alamdari
Polycystic ovary syndrome (PCOS), affecting 5-10% of reproductive-aged women, is linked to metabolic disturbances such as insulin resistance, obesity, and lipid imbalance, which may elevate cardiovascular disease (CVD) risk. The relationship between PCOS and clinical cardiovascular events remains unclear. This meta-analysis evaluates the association between PCOS and cardiovascular and cerebrovascular events, including myocardial infarction (MI), stroke, ischemic heart disease (IHD), and overall CVD. We conducted a systematic review and meta-analysis of observational cohort studies published up to August 2024. Studies investigating the association between PCOS and cardiovascular or cerebrovascular events were included. Hazard ratios (HR) were used to assess mortality risk, while odds ratios (OR) evaluated CVD incidence. Statistical analyses were performed using STATA software, with publication bias assessed via funnel plots. Nineteen cohort studies, involving 1,222,912 participants, were analyzed. Women with PCOS had a significantly higher risk of stroke [OR: 1.89, 95% confidence interval (CI): 1.22-2.55]. However, no significant associations were found between PCOS and overall CVD (HR: 1.80, 95% CI: 5.43-9.04), MI (HR: 2.68, 95% CI: 0.69-4.82), or IHD (HR: 2.68, 95% CI: 0.69-4.67). Additionally, there was no significant increase in cardiovascular or all-cause mortality. This meta-analysis highlights that women with PCOS are at an increased risk of stroke, but no conclusive evidence links PCOS to other cardiovascular outcomes or mortality. Clinicians should prioritize stroke prevention in this population. Further large-scale, long-term studies are needed to clarify the cardiovascular risks associated with PCOS.

4 September 2024 in Journal of Turkish Society of Obstetric and Gynecology
Verified
Journal Article
Open access
FZFaezeh Zakerinasab
Faezeh Zakerinasab
QBQumars Behfar
Qumars Behfar
RPReza Parsaee
Reza Parsaee
FMFariba Arbab Mojeni
Fariba Arbab Mojeni
AAArina Ansari
Arina Ansari
RKReza Khademi
Reza Khademi
The effects of growth hormone supplementation in poor ovarian responders undergoing In vitro fertilization or Intracytoplasmic sperm injection: A systematic review and meta-analysis of randomized controlled trials - Turkish Journal of Obstetrics and Gynecology

23 July 2026 in Cardiovascular Diabetology – Endocrinology Reports
Verified
Journal Article
Open access
PDF file
RKReza Khademi
Reza Khademi
SSSaeed Shoar
Saeed Shoar
Heart failure (HF) is a major cardiovascular complication of type 2 diabetes mellitus (T2DM). Sodium–glucose cotransporter-2 inhibitors (SGLT2is) and

3 December 2025 in The Egyptian Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
SSSaba Rismantab Sani
Saba Rismantab Sani
HTHamed Taheri
Hamed Taheri
AAAmirhesam Amirbeik
Amirhesam Amirbeik
PDParisa Alsadat Dadkhah
Parisa Alsadat Dadkhah
FCFatemeh Chichagi
Fatemeh Chichagi
NDNiloofar Deravi
Niloofar Deravi
Background & aims: This research aimed to assess how long-term fluctuations in glycemic indicators (FPG and HbA1c), measured by the coefficient of variation (CV), influence the risk of all-cause mortality in people with type 2 diabetes. Methods: A review of all literature related to the variability of glycemic indicators published up to June 2025 was conducted using PubMed, Scopus, and Google Scholar. A total of 3,663 articles were found and evaluated based on the title, introduction, and full text, leading to the selection of 15 studies for the meta-analysis. Meta-analysis was performed using a random-effects model. Subgroup and meta-regression analyses were used to explore sources of heterogeneity. Results: Fifteen studies ( n = 584,237) were included. Higher glycemic variability was generally linked to increased mortality risk, but this connection showed extreme statistical heterogeneity (I² >85% for both HbA1c-CV and FPG-CV). Therefore, single pooled estimates (e.g., HR: 0.39 for HbA1c-CV) were unreliable and required stratified interpretation; initial inverse associations were corrected after harmonizing effect coding (Table S1). Importantly, meta-regression revealed that cohort mean age was the strongest moderator, explaining nearly 48.3% (R² = 48.3%) of the between-study heterogeneity. The prognostic link was notably stronger in younger populations, suggesting a diminished effect in older adults due to competing risks. Sensitivity analyses confirmed the consistency of the overall effect direction. Conclusions: Long-term glycemic variability is linked to all-cause mortality in type 2 diabetes. Given the extreme heterogeneity, our findings emphasize that age strongly modifies the risk estimates, suggesting that GV is a more potent prognostic marker in younger T2DM populations. Clinically, potential monitoring of GV should be highly individualized and considered hypothesis-generating, particularly in high-risk, younger subgroups. Standardization of metrics and further prospective studies are warranted.

15 April 2026 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
BNBehrang Nooralishahi
Behrang Nooralishahi
MRMohammad Rahmanian
Mohammad Rahmanian
SSShiva Samavat
Shiva Samavat
KJKasra Jafari
Kasra Jafari
MNMohsen Nafar
Mohsen Nafar
RGReza Ghotbein
Reza Ghotbein
Background: This study aims to evaluate renal outcomes and identify key factors influencing estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease(CKD) undergoing coronary artery bypass grafting (CABG). Methods: In a prospective cohort of 100 patients with CKD (mean age 65.5 years; 77% male; most in CKD stage 2 or 3), eGFR was measured at baseline, three months, and six months postoperatively. Generalized Estimating Equations (GEE) were applied to assess longitudinal changes in eGFR and associated predictors. Statistical analyses were performed using Stata 17. Results: Approximately 19% of patients experienced a > 30% decline in eGFR, while over 40% demonstrated improvement at six months. Advanced CKD stage, higher preoperative heart ejection fraction (EF), and longer anesthesia time were associated with greater eGFR decline. Conversely, higher preoperative hemoglobin (Hb) levels, elective surgery, and a history of cerebrovascular accident were associated with improved estimated eGFR trends. Conclusion: Several clinical and procedural factors influence postoperative renal function in CKD patients undergoing CABG. These findings support the development of targeted perioperative strategies to mitigate renal decline. Clinical trial registration: This study does not meet the criteria of a clinical trial and, therefore, was not registered in a clinical trial registry.